Screener
Royalty Pharma RPRX Other income, net (Note 6)
Other income, net (Note 6) at other companies
Other financials
Where this comes from
Reported directly by Royalty Pharma in its filing.
Tagged under the XBRL concept us-gaap:OtherNonoperatingIncomeExpense.
The source filing: Royalty Pharma’s 10-Q, filed August 5, 2026.
- Filed
- Aug 5, 2026, 9:02 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001802768-26-000015
| Line item | For the Three Months Ended June 30, 2026 | For the Three Months Ended June 30, 2025 | For the Six Months Ended June 30, 2026 | For the Six Months Ended June 30, 2025 |
|---|---|---|---|---|
| (Gains)/losses on equity securities | (69,156) | 30,553 | (48,990) | 76,431 |
| Losses on available for sale debt securities | 34,880 | 27,420 | 41,560 | 30,701 |
| Interest income | (5,127) | (8,327) | (11,356) | (19,617) |
| Other non-operating expenses, net | 1,496 | 1,543 | 3,697 | 4,604 |
| Total other expense, net | 51,633 | 117,164 | 146,415 | 216,912 |
| Consolidated net income before tax | 81,486 | 92,635 | 549,741 | 527,068 |
| Income tax expense | — | — | — | — |
| Consolidated net income | 81,486 | 92,635 | 549,741 | 527,068 |
Item 1. CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
FAQ
- What is Royalty Pharma's other income, net (note 6)?
- Royalty Pharma (RPRX) reported other income, net (note 6) of -$1.5M in Q2 2026.
- How has Royalty Pharma's other income, net (note 6) changed year-over-year?
- Royalty Pharma's other income, net (note 6) increased by 3.0% year-over-year, from -$1.54M to -$1.5M.
- What is the long-term trend for Royalty Pharma's other income, net (note 6)?
- Over 4 years (2021 to 2025), Royalty Pharma's other income, net (note 6) has grown at a 26.1% compound annual growth rate (CAGR), from -$5.68M to -$14.35M.
- What does other income, net (note 6) mean?
- This captures miscellaneous financial items that fall outside the scope of core operating activities, such as foreign exchange gains or losses, minor investment income, or non-recurring legal settlements. It serves as a catch-all for peripheral financial events that do not stem from the primary business operations. Investors monitor this to isolate core earnings from transient or incidental financial fluctuations.
Ask your AI about Royalty Pharma's other income, net (note 6).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude